Evaluating Carcinogenic Risks for Firefighters

Jul 9, 2024 | Cancer, Research

A Brief History of the IARC Monographs Program The International Agency for Research on Cancer (IARC) was established in 1965 to address growing concerns about carcinogenic risks. In 1970, an advisory committee recommended creating a compendium on carcinogenic...

First 5T MRI to Offer Whole-Body Imaging Scores FDA Clearance

Jun 5, 2024 | Research

On May 2, 2024, a groundbreaking advancement in medical imaging was achieved as the U.S. Food and Drug Administration (FDA) granted clearance for the first 5T MRI scanner designed for whole-body applications. This milestone was announced by United Imaging, a Houston,...

Breakthrough Discovery: Urine Test for Head and Neck Cancer Detection

Apr 29, 2024 | Cancer, Research

Researchers at the University of Michigan Health Rogel Cancer Center have made a significant breakthrough in cancer detection with the development of a urine-based test. This innovative test detects DNA fragments shed by head and neck tumors, offering a non-invasive...

Unlocking the Power of Low-Cost CT Coronary Calcium Scoring

Apr 22, 2024 | Research

In recent years, the integration of computed tomography (CT) coronary artery calcium (CAC) testing has surged following the 2018 ACC/AHA Cholesterol Guideline recommendation. This low-cost screening tool, typically priced between $50-$150, has become a pivotal...

AHA Introduces “Race-Free” Cardiovascular Disease Risk Assessment Tool

Apr 22, 2024 | Research

The American Heart Association (AHA) recently unveiled its latest risk assessment tool, PREVENT (Predicting Risk of cardiovascular disease EVENTs), aiming to evaluate heart attack, stroke, and heart failure risks. While the tool incorporates established risk factors,...

Adagrasib Combo Shows Promising Outcomes in KRAS G12C–Mutated CRC: KRYSTAL-1 Trial Analysis

Apr 22, 2024 | Cancer, Research

A groundbreaking combination therapy involving adagrasib (Krazati) alongside cetuximab (Erbitux) has demonstrated substantial efficacy and tolerability in individuals with advanced or metastatic colorectal cancer (mCRC) carrying KRAS G12C mutations. These encouraging...